Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
ObjectiveIn the double-blind, phase III, placebo-controlled RUBY randomized clinical trial, dostarlimab plus carboplatin-paclitaxel significantly increased survival among patients with primary advanced or recurrent endometrial cancer (EC). We conducted a cost-effectiveness analysis of dostarlimab in...
Main Authors: | Gengwei Huo, Ying Song, Wei Liu, Hua Guo, Peng Chen |
---|---|
Format: | Article |
Sprog: | English |
Udgivet: |
Frontiers Media S.A.
2024-06-01
|
Serier: | Frontiers in Pharmacology |
Fag: | |
Online adgang: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1391896/full |
Lignende værker
-
Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
af: Gengwei Huo, et al.
Udgivet: (2023-02-01) -
First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
af: Wenjie Liu, et al.
Udgivet: (2023-07-01) -
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
af: Wenjie Liu, et al.
Udgivet: (2024-02-01) -
Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
af: Maojin You, et al.
Udgivet: (2023-09-01) -
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
af: Michele Bartoletti, et al.
Udgivet: (2022-07-01)